Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5

Ovarian cancer is the most common gynecological malignancies in women, with high mortality rates worldwide. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) superfamily which preferentially induces apoptosis of cancer cells. However, acquired resistance to TRAIL hampers its therapeutic application. Identification of compounds that sensitize cancer cells to TRAIL is vital in combating resistance to TRAIL. The effect of kaempferol, a flavonoid enhancing TRAIL-induced apoptosis in ovarian cancer cells, was investigated in this study.

Material/Methods: The cytotoxic effects of TRAIL (25 ng/mL) and kaempferol (20–100 µM) on human ovarian cancer cells OVCAR-3 and SKOV-3 were assessed. Effect of kaempferol on the expression patterns of cell survival proteins (Bcl-xL, Bcl-2, survivin, XIAP, c-FLIP) and apoptotic proteins (caspase-3, caspase-8, caspase-9, Bax) were studied. The influence of kaempferol on expression of DR4 and DR5 death receptors on the cell surface and protein and mRNA levels was also analyzed. Apoptosis following silencing of DR5 and CHOP by small interfering RNA (siRNA), and activation of MAP kinases were analyzed as well.

Results: Kaempferol enhanced apoptosis and drastically up-regulated DR4, DR5, CHOP, JNK, ERK1/2, p38 and apoptotic protein expression with decline in the expression of anti-apoptotic proteins. Further transfection with siRNA specific to CHOP and DR5 indicated the involvement of CHOP in DR5 up-regulation and also the contribution of DR5 in kaempferol-enhanced TRAIL-induced apoptosis.

Conclusions: Kaempferol sensitized ovarian cancer cells to TRAIL-induced apoptosis via up-regulation of DR4 and DR5 through ERK/JNK/CHOP pathways.

MeSH Keywords: Apoptosis • MAP Kinase Kinase 3 • Ovarian Neoplasms • Transcription Factor CHOP

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/903552
Background

Ovarian cancer is most prevalent cancers among women and is the second most frequent gynecological cancer [1]. Ovarian cancer manifests very few symptoms in the initial stages and is usually diagnosed at an advanced stage [2] making treatment of the malignancy difficult [3]. Further, development of chemoresistance also presents a challenge to the clinical management of advanced epithelial ovarian cancer [4]. An effective strategy in cancer treatment is to induce apoptosis of cancer cells. Zhang et al. [5] reported that Pyrvinium, anti-helminthic drug inhibited cell proliferation and induced apoptosis of paclitaxel- and cisplatin-resistant ovarian cancer cells A2278/PTX and SK-OV-3 via down-regulating Wnt/β-catenin signaling pathway. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that specifically induces apoptosis in cancer cells and exhibiting negligible effects on normal cells [6].

TRAIL exerts its effects through its interaction with five receptors – the death receptors DR4/TRAIL-R1 [7], DR5/TRAIL R2 and the decoy receptors – DcR1/TRAIL-R3 [8] and DcR2/TRAIL-R4 [9] and osteoprotegerin, a cytoplasmic receptor [10]. Binding of TRAIL to DR4 and DR5, leads to the enlistment of Fas- associated protein with death domain (FADD) and procaspases-8/-10 [11]. This results in a multi-protein death-inducing signaling complex (DISC) [12] that eventually leads to initiation of the initiator caspases [13] resulting in transduction of apoptosis pathway.

Despite of favorable results, many studies have demonstrated that a several cancer cells are TRAIL-resistant, including malignant tumors such as ovarian cancer, pancreatic cancer, gliomas, malignant melanoma and neuroblastoma [14]. A number of molecular events have been associated with TRAIL-resistance as increased expression of anti-apoptotic proteins such as cellular (FLICE)-like inhibitory protein (c-FLIP), X-linked inhibitor of apoptosis protein (XIAP) and caspase-3, caspase-8, caspase-9, DR4, DR5 were procured from Cell Signaling Technology (Danvers, MA, USA). β-actin, JNK, phospho-JNK, ERK1/2, phospho-ERK1/2, p38 and phospho-p38 were procured from Sigma-Aldrich (St. Louis, MO, USA) and human insulin (0.01 mg/mL).

Flavonoids are natural polyphenols in fruits and vegetables. They possess wide array of biological properties including anti-proliferative, antioxidant and anti-inflammatory activities [20]. Kaempferol and quercetin are flavonoids that belong to the subclass referred to as flavonols. They are commonly present in many foods including grapefruits, onions and tea [21]. Kaempferol has been reported to have numerous health benefits including antioxidant, cardioprotective and anti-carcinogenic effects [22]. Considering the previous studies, we explored kaempferol for possible enhancement of TRAIL-induced apoptosis of ovarian cancer cells.

Material and Methods

Cell lines

OVCAR-3 and SKOV-3 – human ovarian cancer cells were obtained from ATCC and cultured according to their instructions. Briefly, SKOV-3 cells were cultured in RPMI 1640 medium (Invitrogen, CA, USA) supplemented with fetal bovine serum (FBS) (10%). OVCAR-3 cells were also cultured in RPMI 1640, but were supplemented with 20% FBS and bovine insulin (0.01 mg/mL).

Chemicals and reagents

Kaempferol (Sigma-Aldrich, St. Louis, MO, USA) and human TRAIL from PeproTech (Rocky Hill, NJ, USA) were used in the study. Antibodies against Bcl-xL, Bcl-2, survivin, Bax, c-FLIP, CHOP (CEBP homologous protein), XIAP, caspase-3, caspase-8, caspase-9, DR4, DR5 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and were used for expression analysis. All other analytical-grade chemicals and reagents were from Sigma-Aldrich unless noted otherwise.

Cell viability assay

OVCAR-3 and SKOV-3 – human ovarian cancer cells were seeded into 96-well plates (0.5×10⁴ cells/well) and incubated for 24 h. The cells were then exposed to various concentrations of kaempferol (20–100 μM) for 24 h. Cells were then incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). After 4 h, the formed formazan crystals were dissolved in DMSO and the absorbance was measured at 570 nm using a multiscan spectrum (Thermo Electron Co., Vantaa, Finland). The inhibition of cell proliferation was estimated using the formula – (A570 control cells – A570 treated cells)/A570 control cells ×100%.

5097

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Kaempferol sensitizes ovarian cancer cells

Zhao Y. et al.:
Kaempferol sensitizes ovarian cancer cells
© Med Sci Monit, 2017; 23: 5096-5105

LAB/IN VITRO RESEARCH

Live/dead assay
To assess apoptosis following exposure to various concentrations of kaempferol (25, 50 and 100 µM), the Live/Dead kit assay (Invitrogen, CA, USA) was performed. The assay ascertains membrane integrity and intracellular esterase activity as a measure of apoptosis using non-fluorescent polyatomic dye, calcein-AM. The live cells retain the dye, thereby producing intense green fluorescence through conversion of esterase and the ethidium homodimer binds to nucleic acids inside the damaged/dead cells and gives a bright red fluorescence. Briefly, OVCAR-3 and SKOV-3 - human ovarian cancer cells that were treated with kaempferol and or TRAIL (25ng/mL) were stained with the Live/Dead reagent (5 µmol/L ethidium homodimer and 5 µmol/L calcein-AM) and incubated at 37°C for 30 min. The cells were examined for fluorescence under a fluorescence microscope (Labophot-2, Nikon).

Analysis of apoptosis by Annexin V assay
Human ovarian carcinoma cells, OVCAR-3 and SKOV-3 were incubated with kaempferol (50 or 100 µM) and/or TRAIL (25 ng/mL) for 24 h. Percentage of apoptosis was detected using Annexin V-FITC detection kit II (BD Biosciences Pharmingen, San Diego, CA, USA). Following treatments, the cancer cells were incubated for about 30 min at room temperature with 5 µL annexin V-FITC reagent and were examined using a flow cytometer (FACS Calibur, BD Biosciences).

Analysis of DR4 and DR5 expression
The cell-surface expression of death receptors DR4 and DR5 in the ovarian carcinoma cells treated with kaempferol (50 and 100 µM) for 24 h were assessed using mouse anti-human DR4 or DR5 monoclonal antibodies conjugated with phycoerythrin (R&D Systems). The cells were treated with the antibodies and incubated for 45 min at 4°C and were examined by flow cytometry [23].

Analysis of gene expression by real-time PCR
Using TRIzol reagent (Invitrogen, CA, USA) total RNA was isolated from tumor cells according to the manufacturer’s protocol. Quantitative real-time PCR for DR4, DR5 and GAPDH genes was carried out as previously described by Wei et al. [24]. The primer sequences DR4 5’-TTGTGTCACCAGGATCTCA-3’ and 5’- GTCACTCC AGGGCGTACAAT-3’ [25], DR5 5’-ACT CCTGAAATGACTACGT-3’ and 5’-ATCCCAAGTGAA CTTGA GCC-3’ [25], GAPDH, 5’-GTCATCATGACAACTTTGG-3’ and 5’-GA GCTTGACAAAGTGTCGT-3’ [26] were used. The relative expression levels of DR4 and DR5 genes were standardized with the expression of internal control (GAPDH).

Expression of DR5 and CHOP were analyzed following silencing with 25-nucleotide siRNA (Invitrogen, CA, USA) to assess the influence of kaempferol on DR5 and CHOP expression. The carcinoma cells OVCAR-3 and SKOV-3 were transfected with siRNA oligonucleotides (30 mmol/L) using lipofectamine 2000 (Invitrogen, CA, USA) as per the manufacturer’s protocols. Following transfection, cells were treated with kaempferol (100 µM) for 12 h and then incubated with TRAIL (25 ng/mL) for 24 h [27]. The cells were collected and analyzed for expression and for apoptosis. The percentage of apoptosis was assessed by Live/Dead assay as described earlier.

Western blot analysis
Proteins extracted from the cells treated with kaempferol (50 and 100 µM) and/or TRAIL (25 ng/mL) for 24 h were subjected to western blot analysis. Western blot analysis was performed as described previously by Sung et al. [28]. Following treatments, the cells were incubated in 0.5 mL of ice-cold whole-cell lysate buffer (5 M NaCl, 10% Nonident P-40, 0.2 M sodium orthovanadate, 1 M HEPES, 0.1 M EDTA, 0.1 M phenylmethylsulfonlfuoride, 1 M sodium fluoride, 2 µg/mL aprotinin and 2 µg/mL leupeptin) on ice for 30 min. The isolated proteins from the cell lysates were separated by SDS-PAGE and electrotransferred to nitrocellulose membranes. Respective antibodies were used for hybridization and the immune-reactive bands were analyzed by enhanced chemiluminescence (GE Healthcare). The band densities were normalized to those of control – β-actin using anti-β-actin (Cell Signaling Technology Company, USA).

Statistical analysis
The results are reported as means ±SDs, from three or six different experiments. Data were evaluated using one-way analysis of variance (ANOVA) followed by Duncan’s multiple range test (DMRT) using the SPSS software (ver. 16.0). P values <0.05 were considered to indicate statistical significance.

Results
Kaempferol inhibited cancer cell proliferation
Kaempferol at 20–100 µM concentrations efficiently inhibited the proliferation of ovarian cancer cells OVCAR-3 and SKOV-3. Upon incubation with kaempferol, the cell viability significantly (p<0.05) decreased (Table 1). While 20 and 40 µM kaempferol reduced the viability, doses above 40 µM brought more reduction in cell viability in both the cell lines.

Transfection with siRNA
Expression of DR5 and CHOP were analyzed following silencing with 25-nucleotide siRNA (Invitrogen, CA, USA) to assess the influence of kaempferol on DR5 and CHOP expression. The carcinoma cells OVCAR-3 and SKOV-3 were transfected with siRNA oligonucleotides (30 mmol/L) using lipofectamine 2000 (Invitrogen, CA, USA) as per the manufacturer’s protocols. Following transfection, cells were treated with kaempferol (100 µM) for 12 h and then incubated with TRAIL (25 ng/mL) for 24 h [27]. The cells were collected and analyzed for expression and for apoptosis. The percentage of apoptosis was assessed by Live/Dead assay as described earlier.

NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]

5098
Kaempferol enhanced TRAIL-induced apoptosis

Live/Dead assay for determining cell viability was performed after exposure to 25, 50, or 100 µM kaempferol. Exposure to 50 µM concentration resulted in 49.09% in OVCAR-3 cells and 48.93% in SKOV-3 cells. Striking increases \( p < 0.05 \) were observed in treatment with 100 µM kaempferol as compared with lower doses of 25 or 50 µM. However, exposure to TRAIL and kaempferol at 100 µM interestingly, bought a multi-fold increase in cytotoxicity levels to 73.19% in OVCAR-3 and 78.90% in SKOV-3 cells (Table 2A). TRAIL alone caused viability of about 36.16% and 37.88% in SKOV-3 and OVCAR-3 cells respectively.

Translocation of membrane phosphatidylserine to the extracellular surface of the membrane from the cytoplasmic interface is a primary indicator of apoptosis. Annexin V/PI staining

### Table 1. Cytotoxicity of various concentrations of kaempferol as determined by MTT assay.

|                   | SKOV-3     | OVCAR-3    |
|-------------------|------------|------------|
| Control           | 99.21±0.58 | 99.14±0.75 |
| 20 µM Kaempferol  | 85.62±3.09 | 86.36±3.62 |
| 40 µM Kaempferol  | 69.73±1.67 | 74.09±1.54 |
| 60 µM Kaempferol  | 48.00±2.06 | 49.90±1.78 |
| 80 µM Kaempferol  | 45.90±1.54 | 47.92±1.78 |
| 100 µM Kaempferol | 36.17±2.05 | 40.26±1.28 |

Values are represented as mean ±SD, n=6. \( * \) Denotes statistical significance at \( p < 0.05 \) compared against control; \( a-f \) represents values of various treatment on the same cell line that differ from each other at \( p < 0.05 \) as determined by one-way ANOVA followed by DMRT analysis.

### Table 2A. Kaempferol enhanced TRAIL-induced apoptosis in ovarian cancer cells.

|                   | SKOV-3     | OVCAR-3    |
|-------------------|------------|------------|
| Control           | 2.1±0.66   | 1.7±0.59   |
| 25 µM Kaempferol  | 29.25±1.98 | 35.60±2.06 |
| 50 µM Kaempferol  | 48.93±2.73 | 49.09±3.02 |
| 100 µM Kaempferol | 66.12±4.36 | 60.05±3.97 |
| 25 µM Kaempferol + TRAIL | 59.84±3.5 | 62.96±3.86 |
| 50 µM Kaempferol + TRAIL | 63.19±2.13 | 68.90±2.50 |

### Table 2B. Kaempferol enhanced TRAIL-induced apoptosis in ovarian cancer cells as determined by Annexin V assay.

|                   | SKOV-3     | OVCAR-3    |
|-------------------|------------|------------|
| Control           | 1.59±0.05  | 1.98±0.10  |
| 50 µM Kaempferol  | 30.39±1.56 | 36.12±1.32 |
| 100 µM Kaempferol | 57.90±2.86 | 60.01±3.05 |
| 50 µM Kaempferol + TRAIL | 56.12±1.98 | 58.17±2.12 |
| 100 µM Kaempferol + TRAIL | 68.54±3.71 | 72.15±3.50 |
| TRAIL (25 ng/ml)  | 28.70±1.75 | 31.22±1.53 |

Values are represented as mean ±SD, n=6. \( * \) Denotes statistical significance at \( p < 0.05 \) compared against control; \( a-f \) represents values of various treatment on the same cell line that differ from each other at \( p < 0.05 \) as determined by one-way ANOVA followed by DMRT analysis.
assay was performed to assess the integrity of the cell membrane. The results presented in Table 2A and 2B reveals that the combined exposure to TRAIL and kaempferol at 50 and 100 µM could induce more robust apoptosis in the cancer cells than the exposure to either TRAIL or kaempferol at both the doses. The results suggest that kaempferol was able to effectively enhance TRAIL-induced apoptosis.

Kaempferol up-regulated the cell surface expression of DR4 and DR5

TRAIL is known to induce apoptosis through its interaction with death receptors – DR4 and DR5 which eventually interact with FADD leading to the sequential activation of initiator caspase-8 and caspase-3 [29]. We were particularly interested to know if kaempferol-induced apoptosis is associated with up-regulation of the cell surface expression of DR4 and DR5 in the ovarian cancer cells. Exposure to kaempferol resulted in a significant (<0.05) increase in the expression of DR4 and DR5 in a dose-dependent manner. However, kaempferol at both the doses were more effective on the expression of DR5 than DR4. Further, SKOV-3 cells presented striking expression of DR5 than the OVCAR-3 cells following exposure to 50 and 100 µM of kaempferol (Figure 1).

Furthermore, to examine the influence of kaempferol on the expression of DR4 at the mRNA level, RT-PCR was performed. Kaempferol potentially induced the expression of DR5 and DR4 in dose-dependent way (Figure 2A, 2B). Kaempferol induced significant effects on the mRNA expression levels of DR4 and
DRS and the same was observed to be in line with the protein level of the death receptors as determined by western blot analysis (Figure 3). However, the up-regulation of DRS was more pronounced than DR4.

DR5 expression is reported to be regulated at the transcriptional level through CHOP upon interacting at CHOP-binding site in the DR5 [30]. Previous studies have shown that the induction of death receptor by chemotherapeutic agents is mediated through the activation of CHOP [31]. Kaempferol at 50 and 100 µM caused marked (p<0.05) increase in the expression of CHOP. Enhanced expression of CHOP as observed was in line with expression level of DRS, suggesting that elevated CHOP also might had possibly induced the expression of DR5 that consequently resulted in a marked decline in cytotoxicity percentage. Values are represented as mean ±SD, n=6; a denotes statistical significance at p<0.05 compared against control as determined and b–f denotes values within the same group that differ from each other at p<0.05 as determined by one-way ANOVA followed by DMRT analysis. (A) Cytotoxicity exhibited after transfection with siRNA specific for DRS under the influence of kaempferol. Transfection with siRNA specific for DRS resulted in a significant decrease in the expression of DRS, (L1 – Control; L2 – 100 µM Kaempferol; L3 – 100 µM Kaempferol+TRAIL; L4 – 100 µM Kaempferol+DS siRNA; L5 – 100 µM Kaempferol+TRAIL+DS siRNA; L6 – TRAIL (25 ng/mL); L7 – TRAIL (25 ng/mL)+DS siRNA; L8 – DS siRNA). (B) Cytotoxicity exhibited after transfection with siRNA under the influence of kaempferol. Transfection with siRNA specific for DRS resulted in a significant decrease in the expression of DRS that consequently resulted in a marked decline in cytotoxicity percentage. Values are represented as mean ±SD, n=6; a denotes statistical significance at p<0.05 compared against control as determined and b–f denotes values within the same group that differ from each other at p<0.05 as determined by one-way ANOVA followed by DMRT analysis. (C) Cytotoxicity exhibited after transfection with siRNA under the influence of kaempferol. Transfection with siRNA specific for CHOP resulted in a significant decrease in the expression of CHOP, (L1 – Control; L2 – 100 µM Kaempferol; L3 – 100 µM Kaempferol+TRAIL; L4 – 100 µM Kaempferol+DS siRNA; L5 – 100 µM Kaempferol+TRAIL+DS siRNA; L6 – TRAIL (25 ng/mL); L7 – TRAIL (25 ng/mL)+DS siRNA; L8 – DS siRNA). (D) Cytotoxicity exhibited after transfection with siRNA under the influence of kaempferol. Transfection with siRNA specific for CHOP resulted in a significant decrease in the expression of CHOP that consequently resulted in a marked decline in cytotoxicity percentage. Values are represented as mean ±SD, n=6; a denotes statistical significance at p<0.05 compared against control as determined and b–g denotes values within the same group that differ from each other at p<0.05 as determined by one-way ANOVA followed by DMRT analysis. (E) Cytotoxicity exhibited after transfection with siRNA under the influence of kaempferol. Transfection with CHOP siRNA strikingly reduced the DR5 expression levels that was in line with cytotoxicity levels observed with CHOP siRNA, suggesting the involvement of CHOP in DRS up-regulation and expression, (L1 – Control; L2 – 100 µM Kaempferol; L3 – 100 µM Kaempferol+TRAIL; L4 – 100 µM Kaempferol+DS siRNA; L5 – 100 µM Kaempferol+TRAIL+DS siRNA; L6 – TRAIL (25 ng/mL); L7 – TRAIL (25 ng/mL)+DS siRNA; L8 – DS siRNA).
CHOP mediates kaempferol-induced up-regulation of DR5 is required for TRAIL-induced apoptosis

To further assess the involvement of CHOP and DR5 in kaempferol-induced increase in TRAIL-induced apoptosis, siRNAs specific to DR5 and CHOP were employed. Transfection of the cancer cells with siRNA for DR5 caused reduction in DR5 expression (Figure 4A–4E). However, TRAIL and 100 µM kaempferol caused slight up-regulation of DR5. In the cells that were not exposed to DR5 siRNA, elevated DR5 expression was observed. In cells transfected with siRNA for CHOP, decrease in DR5 expression level was found indicating the involvement of CHOP in DR5 expression. While kaempferol caused elevated DR5 levels, the cells not transfected with CHOP siRNA exhibited pronounced expression than cells exposed, resulting in apoptosis. This was further supported by the increase in the apoptosis counts of the cancer cells following cell viability assay. In cells transfected with siRNA, the viability percentage of the cancer cells was high. The results suggest that CHOP and DR5 are needed for TRAIL-induced apoptosis of the cancer cells.

Kaempferol-induced death receptor up-regulation requires MAP kinases

We studied whether kaempferol influenced the activation of MAP kinases – ERK1/2, p38 MAPK, and JNK. Incubation with kaempferol caused significant (p<0.05) up-regulation in the expression of ERK1/2, JNK and p38. Kaempferol caused multi-fold increase in the level of phosphorylated ERK1/2 and JNK. Though we observed a considerable increase in p-p38 levels, it was not significant. Kaempferol induced enhancement in the phosphorylation level was more following exposure to 100 µM, than other lower doses used (Figure 5A, 5B).

Kaempferol modulates the expression of apoptotic pathway proteins

Bonding of TRAIL to the death receptors (DR4 and DR5) is pivotal for initiation of apoptosis. This interaction results in the initiation of the caspase cascade. The effects of kaempferol on TRAIL-induced activation of caspases was assessed where kaempferol at 50 and 100 µM strikingly increased (p<0.05) the expression of caspase-3,-8 and -9 in both OVCAR-3 and SKOV-3 cell lines. However, the combined exposure of TRAIL and kaempferol had more impact in the caspase expression with 100 µM presenting significant effect than the lower doses (Figure 6A, 6B).

OVCAR-3 and SKOV-3 cells treated with different concentrations of kaempferol and/or TRAIL were evaluated for expression of cell survival proteins. Kaempferol caused significant (p<0.05) inhibition on the expressions of Bcl-xL, Bcl-2, survivin, c-FLIP and XIAP, while up-regulating the pro-apoptotic protein, Bax (Figure 6A, 6B). While 100 µM brought out a decrease in the expression of these anti-apoptotic proteins, the combined effects of TRAIL and kaempferol was more significant than kaempferol or TRAIL when used alone. Collectively, the results suggest that kaempferol potentiated the down-regulation of cell survival proteins.
survival proteins probably by similar mechanisms as TRAIL, suggesting that kaempferol potentiated TRAIL-induced apoptosis.

**Discussion**

Despite promising effects of TRAIL on cancer cells, accumulating reports have made it evident that human tumors are gaining resistant to TRAIL and occurrences of acquiring resistance to TRAIL-mediated cell death [32]. It has been postulated that in tumors resistant to TRAIL, the cell survival signals normally become prominent due to deficiencies in the apoptotic pathways. Signaling pathway dysfunctions including the altered expression of the DRs, the Fas-associated death domain, or caspase-8 [33], overexpression of anti-apoptotic Bcl-2 family proteins, Mcl-1, survivin, and cFLIP, a caspase-8 inhibitor [34], and activation of NF-κB [35], enhanced expressions of XIAP have been observed in many tumor cell lines that may lead to TRAIL resistance by inhibiting caspases [36].

Depending on the survival pathway elicited and/or the factors contributing to resistance, TRAIL-resistant cancers possibly lead to an improved survival and even tumor cells migration despite treatment with TRAIL [37]. Thus, it becomes pivotal to identify novel compounds that could effectively sensitize tumor cells to TRAIL-induced apoptosis and can be possibly combined with TRAIL to amplify its apoptotic effects [34].

Studies indicate that ovarian cancers also exhibit resistance to TRAIL through various molecular events [38]. Recent studies have demonstrated that exposure to gingerol and quercetin could sensitize cancer cells [39].

We investigated whether kaempferol was able to sensitize SKOV-3 and OVCAR-3 human ovarian cancer cells to TRAIL.

Kaempferol at 20–100 µM decreased SKOV-3 and OVCAR-3 cells viability, suggesting its anti-proliferative efficacy. Furthermore, the combined exposure to kaempferol and TRAIL dramatically increased the apoptotic cell counts as compared to cells treated with either kaempferol or TRAIL, suggesting that kaempferol...
effectively potentiated the effects of TRAIL. In addition, downregulated expression of anti-apoptotic proteins, Bcl-2, Bcl-xL and survivin were observed following exposure to kaempferol. The ratio between pro-apoptotic and anti-apoptotic members of the Bcl-2 family determines the transduction of death signal. Down-regulation of Bcl-xL, Bcl-2 and survivin expression is known to promote sensitivity to TRAIL-mediated cell death [40]. Further, resistance to TRAIL has also been correlated with over-expressions of c-FLIP and XIAP [34,40]. It has been shown that the phytochemical drugs, casticin and car-damolin inhibit XIAP and enhanced TRAIL-mediated apoptosis [41]. Thus, kaempferol-induced down-regulation of XIAP and c-FLIP could also have contributed to the caspase cascade activation, that is evident by the significant up-regulation of caspase-3, caspase-8, caspase-9 and pro-apoptotic protein (Bax) as well. The differences observed in the expression patterns were dose-dependent, where 100 µM kaempferol combined with TRAIL had greater influence.

Interaction with DR4 and DR5 receptors triggers the transduction of the apoptotic pathway. The higher expression of these receptors on tumor cells contributes to TRAIL-induced cell death [42]. Thus, for any changes either at the protein level and/or cell surface level, TRAIL receptors have profound effects on TRAIL, as a death-inducing ligand. Dysregulated expression levels have been reported in several TRAIL-resistant cancers [43] subsequent up-regulation of the receptors contributes to promote apoptosis. Kaempferol caused significant up-regulation in the expression of DR4 and DR5 on the surface of SKOV-3 and OVCAR-3 cells and also enhanced expression at the gene and protein level. Silencing of DR5 gene was executed to understand the contribution of DR5 up-regulation in kaempferol induced TRAIL-mediated apoptosis. Transfection of the cells with DR5 siRNA affected DR5 expression and apoptotic cell counts. While combined exposure to kaempferol and TRAIL presented a slight increase in apoptotic cells, increase in apoptosis in cancer cells that were not transfected with siRNA was more robust, indicating the contribution of DR5 in TRAIL-mediated cell death.

Conclusions

Observations of our study suggest that kaempferol effectively sensitized the ovarian cancer cells and enhanced TRAIL-induced apoptosis by significantly upregulating the death receptors and through the activation of CHOP and MAP kinases. Thus, kaempferol could possibly be employed in combined therapy with TRAIL in the treatment of TRAIL-resistant tumors.

Conflicts of interest

None.

References:

1. Ferlay J, Shin H, Bray F et al: Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008: Int J Cancer, 2010; 127: 2893–917
2. Buyss Ss, Partridge E, Black A et al: Effect of screening on ovarian cancer mortality. The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA, 2011; 305: 2295–303
3. Deraco M, Rossi CR, Pennacchioli E et al: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study. Tumori, 2003; 87: 120–26
4. Agarwal R, Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003; 3: 502–16
5. Zhang C, Zhang Z, Zhang S et al: Targeting of Wnt/β-catenin by anthelmin- tic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemo-therapy. Med Sci Monit, 2017; 23: 266–75
6. Ashkenazi A, Pai RC, Fong S et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investigation, 1999; 104: 155–62
7. Pan G, O’Rourke K, Chinnaiyan AM et al: The receptor for the cytotoxic li-gand TRAIL. Science, 1997; 276: 111–13
8. Pan G, Ni J, Wei YF et al: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 1997; 277: 815–18
9. Marsters SA, Sheridan JP, Petti RM et al: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol, 1997; 7: 1003–6
10. Emery JG, McDonnell P, Burke MB et al: Osteoprotegerin is a recep-tor for TRAIL. Science, 1997; 277: 111–13
11. Medema JP, Scaffidi C, Kischkel FC et al: FLICE is activated by association with the CD95 death inducing signaling complex (DISC). EMBO J, 1997; 16: 2794–804
12. Kischkel FC, Hellbardt S, Behrmann I et al: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor: EMBO J, 1995; 14: 5597–88

MAP kinases transduce various extracellular stimuli and are vital for the sustainment of various intracellular processes like that of cell development and growth, apoptosis and re-actions to various external stresses [14]. The MAP kinases – JNK, ERK and p38 kinase have been found to be activated in response to TRAIL stimulation [14] and also regulate the expression of DR4 and DR5 [28]. Kaempferol caused up-regulation of the phosphorylated forms indicating activation of JNK, p-38 and ERK1/2 in a dose-dependent way. Gingerol, gossypol and quercetin enhanced TRAIL-induced apoptosis through activation of MAP kinases [28, 39].
13. Kischkel FC, Lawrence DA, Chuntharapai A et al: Apo2L/TRAIL-dependent recruitment of endogenous FAOΔD and caspase-8 to death receptors 4 and 5. Immunity, 2000; 12: 611–20

14. Mellier G, Huang S, Shenoy K, Pervaiz S: TRAILing death in cancer. Mol Aspects Med, 2010; 31: 93–112

15. Inoue T, Shiraki K, Fuke H et al: Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs, 2006; 17: 261–68

16. Zhang L, Zhu H, Teraishi F et al: Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia, 2005; 7: 594–602

17. Jung YH, Heo J, Lee YJ et al: Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci, 2010; 86: 351–57

18. Han MA, Woo SM, Min KJ et al: 6-Shogaol enhances renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated cytochrome c release and down-regulation of c-FLIP(L) expression. Chem Biol Interact, 2015; 228: 69–78

19. Henrich CJ, Brooks AD, Erickson KL et al: Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. Cell Death Dis, 2015; 6: e1666

20. Harborne JB, Williams CA: Advances in flavonoid research since 1992. Phytochemistry, 2000; 55: 481–504

21. Ross JA, Kasum CM: Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr, 2002; 22: e19–e34

22. Casagrande F, Darbon JM: Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: Regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol, 2001; 61: 1205–15

23. Prasad S, Ravindran J, Sung B et al: Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther, 2010; 9: 856–68

24. Wei G, Zhang GM, Liu Y et al: IFN-γ withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumour in-tegrin αvβ3 signaling. Int J Cancer, 2008; 123: 702–8

25. Frese S, Frese-Schaper M, Andres AC et al: Cardiac glycosides initiate Apo2L/TRAIL induced apoptosis in non-small cell lung cancer cells by upregulation of death receptors 4 and 5. Cancer Res, 2006; 66: 5867–74

26. Yang XC, Tu CX, Luo PH et al: Antimetastatic activity of MONCPT in preclinical melanoma mice model. Invest New Drugs, 2010; 28: 800–11

27. Yadav VR, Sung B, Prasad S et al: Celastrol suppresses invasion of colon and pancreatic cancer cells through the down-regulation of expression of CXCR4 chemokine receptor. J Mol Med, 2010; 88: 1243–53

28. Sung B, Ravindran J, Prasad S et al: Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem, 2010; 285: 35416–27

29. Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol, 2003; 3: 745–56

30. Yamaguchi H, Wang HG: CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem, 2004; 279: 45495–502

31. Lee TJ, Um HJ, Mindo S et al: Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med, 2009; 46: 1639–49

32. LeBlanc HN, Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 2003; 10: 66–75

33. Wagner KW, Punnose EA, Januario T et al: Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med, 2007; 13: 1070–77

34. Zhang J, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther, 2005; 12: 228–37

35. Ravi R, Bedi GC, Engstrom LW et al: Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κappa-B. Nat Cell Biol, 2001; 3: 409–16

36. Deveraux QL, Takahashi R, Salvesen GS, Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 1997; 388: 300–4

37. Scicchiero P, Gonnelli A, Carnevale E et al: TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation, 2003; 107: 2250–56

38. Horak P, Pilis D, Kaider A et al: Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: Overexpression of FULP and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res, 2005; 11: 8585–91

39. Lee DH, Kim DW, Jung CH et al: Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells. Toxicol Appl Pharmacol, 2014; 279: 253–65

40. Fulda S, Meyer E, Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 2002; 21: 2283–94

41. Tang SY, Zhong MZ, Yuan GJ et al: Cardiocrin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells. Oncol Rep, 2013; 29: 474–80

42. Kruyt FA: TRAIL and cancer therapy. Cancer Lett, 2008; 263: 14–25

43. Fisher MJ, Virmani AK, Wu L et al: Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res, 2001; 7: 1688–97

44. Wang H, Gao W: DJ-1 Expression in cervical carcinoma and its effects on cell viability and apoptosis. Med Sci Monit, 2016; 22: 2943–49

45. Liang M, Lin X, He R et al: Decoy Receptor 3 (DcR3) as a biomarker of tumor deterioration in female reproductive cancers: A Meta-Analysis. Med Sci Monit, 2016; 22: 1850–57